MetaOptics Ltd (Catalist: 9MT) (“MetaOptics” or the “Company”, and together with its subsidiaries, the “Group”) recently ...
Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 ...
Vietnam Investment Review on MSN
MetaOptics advances growth strategy and leadership transition
SINGAPORE, March 20, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") recently announced a series of strategic ...
Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results